Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 118, 2013 - Issue 2
Journal homepage
1,083
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Ruling out cardiac failure: Cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography

Maria-José FerrandisDepartment of Clinical Chemistry, Blekinge County Hospital, Karlskrona, Sweden;Department of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala, Sweden
,
Ingvar RydenDepartment of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala, Sweden;Department of Clinical Chemistry, Kalmar County Hospital, Kalmar, Sweden;Roche Diagnostics, Stockholm, Sweden
,
Tomas L. LindahlDepartment of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
&
Anders LarssonDepartment of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
Pages 75-79 | Received 09 Nov 2012, Accepted 15 Nov 2012, Published online: 12 Dec 2012

References

  • Bhardwaj A, Januzzi JL Jr. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit Pathw Cardiol. 2009;8:146–50.
  • Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation. 2011;123:e18–e209.
  • On the horizon in heart failure. Lancet. 2011;378:637.
  • Brutsaert DL. Cardiac dysfunction in heart failure: the cardiologist's love affair with time. Prog Cardiovasc Dis. 2006;49:157–81.
  • Ross JS, Chen J, Lin Z, Bueno H, Curtis JP, Keenan PS, Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail. 2010;3:97–103.
  • Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O'Connor CM, Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail. 2011;4:628–36.
  • Schlendorf KH, Kasper EK. Use of novel and conventional biomarkers for management of patients with heart failure. Curr Treat Options Cardiovasc Med. 2011;13:475–88.
  • Dokainish H. Combining tissue Doppler echocardiography and B-type natriuretic peptide in the evaluation of left ventricular filling pressures: review of the literature and clinical recommendations. Can J Cardiol. 2007;23:983–9.
  • Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13:1–207; iii.
  • Hino J, Tateyama H, Minamino N, Kangawa K, Matsuo H. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun. 1990;167:693–700.
  • Sudoh T, Maekawa K, Kojima M, Minamino N, Kangawa K, Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun. 1989;159:1427–34.
  • Norton C, Georgiopoulou VV, Kalogeropoulos AP, Butler J. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis. 2011;54:78–85.
  • Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wielders JP, Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail. 2011;13:518–27.
  • Lee KH, Kim JY, Koh SB, Lee SH, Yoon J, Han SW, N-terminal pro-B-type natriuretic peptide levels in the Korean general population. Korean Circ J. 2010;40:645–50.
  • Michtalik HJ, Yeh HC, Campbell CY, Haq N, Park H, Clarke W, Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol. 2011;107:1191–5.
  • Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–7.
  • Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:1881–9.
  • Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124:2865–73.
  • Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388–442.
  • McIntyre HF. Leveraging guidelines: understanding heart failure, organizing care. Commentary on the 2010 NICE chronic heart failure guideline update. Eur J Heart Fail. 2011;13:14–17.
  • Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824–39.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.